Coronavirus

Intranasal Covid-19 vaccine production commences at Pune’s Serum Institute of India

Last updated on February 17th, 2023 at 01:04 pm

 Intranasal vaccine for Covid-19 virus SARS-CoV-2 is not under any clinical trial currently, but Serum Institute of India has started production of an intranasal vaccine candidate, informed Union Health Minister Dr. Harsh Vardhan on Monday. Various Covid-19 vaccine candidates are currently under human trials in India.

Dr. Harsh Vardhan said, “Flumist nasal spray is a vaccine that is sprayed into the nose to help protest against influenza; it is not a Covid-19 vaccine. At present in India, there is no intranasal Covid vaccine which is under clinical trials. However, Serum Institute of India has begun manufacturing Codagenix CDX 005, which is an intranasal live attenuated vaccine candidate for Sars-Cov-2.”

The phase 1 trials will take place in the US in St. Louis University’s vaccine and treatment evaluation unit, on getting regulatory approval, Bharat Biotech will pursue further stages of clinical trials in India

Dr. Harsh Vardhan

“Pre-clinical animal studies have already been completed and Codagenix expects to initiate a phase 1 clinical first in humans trial in the United Kingdom by the end of 2020. Further, Serum India plans to undertake clinical developments of this vaccine candidate in India,” he added.

As a part of the sixth episode of Sunday Samvaad, the Minister was responding to the questions on his social media accounts.  He relayed that India’s Bharat Biotech has also signed an agreement with Washington University School of Medicine. Through this trials will be conducted to produce and market an intranasal vaccine for Covid-19.

“The phase 1 trials will take place in the US in St. Louis University’s vaccine and treatment evaluation unit, on getting regulatory approval, Bharat Biotech will pursue further stages of clinical trials in India,” he said.

Dr. Harsh Vardhan said that Bharat Biotech’s vaccine candidate was being tested on people between 18 and 55 years in phase 1, and for phase 2, it was extended to include participants of ages between 12 and 65 years.

Read: “Sindhu was not happy with the training in national camp”: PV Raman, Sindhu’s father

CV Journalist

Dr. Neha Mathur, a distinguished member of the India Observers team, specializes in Health and Wellness. With a profound commitment to keeping our readers informed, Dr. Neha shares expert insights on health-related topics. Navigate the world of well-being with Dr. Neha's expertise and dedication to your health journey.

Recent Posts

UK Election Results 2024: Rishi Sunak Defeat as Labour Wins Majority

The UK election results are in and it is not as surprising as the election…

July 5, 2024

Budget 2024: Will Modi 3.0 Continue With Welfare Push? Schemes That Got Major Allocations

As the Budget approaches taxpayers are eager to see what benefits the Finance Minister might…

July 5, 2024

5 Great Reasons to Drink Fennel Water for Better Health

Fennel, also referred to as saunf, is a familiar spice among Indian households. It is…

July 5, 2024

‘Terrorism in any form can’t be justified’- PM Modi Condemns Terrorism at SCO Summit

In a powerful statement at the Shanghai Cooperation Organisation (SCO) Council of Heads of State…

July 4, 2024

Hemant Soren Returns as Jharkhand CM with Oath Ceremony on July 7th

After releasing from the jail, Hemant Soren will take oath as the new Chief Minister…

July 4, 2024

List of Tallest Statues in India that have become tourist destinations

Throughout history, various cultures have crafted statues with their inception beginning at ancient times to…

July 4, 2024

This website uses cookies.

Read More